Information
63 Magokjungang 8-ro 3-gil, Gangseo-gu, Seoul, South Korea
+82 2-449-8671
-
-
Overview
- Summary
- Genolution Inc. is a company established in 2006, specializing in molecular diagnostics and RNAi, providing solutions through the development of nucleic acid extraction platforms, equipment, and kits. The company supplies molecular diagnostic, genetic testing, and life science research solutions to laboratories, government agencies, and testing institutions worldwide. Furthermore, it expands its green bio business by leveraging double-stranded RNA (dsRNA) synthesis technology for pest control and the development of next-generation crop protection agents.Genolution Inc. is a company established in 2006, specializing in molecular diagnostics and RNAi, providing solutions through the development of nucleic acid extraction platforms, equipment, and kits. The company supplies molecular diagnostic, genetic testing, and life science research solutions to laboratories, government agencies, and testing institutions worldwide. Furthermore, it expands its green bio business by leveraging double-stranded RNA (dsRNA) synthesis technology for pest control and the development of next-generation crop protection agents.
- Key Products/Technologies
- Nextractor® Nucleic Acid Extraction Instrument Series: Automated systems capable of rapid and cost-effective processing of large sample volumes. Key models include Nextractor® NX-48S (48 samples in 10-25 minutes, 7-inch LCD touch screen, UV sterilization, 25kg), Nextractor® NX-Duo (24 or 96 samples in 15-30 minutes, capable of cfDNA extraction from 24 samples for liquid biopsy in 30-40 minutes, 6-inch touch screen, UV sterilization, 60kg), Nextractor® NX-Jr (1-8 samples in 15 minutes, compact design, UV sterilization, 12kg), and Nextractor® NX-48N (48 samples in 25 minutes).Nextractor® Nucleic Acid Extraction Instrument Series: Automated systems capable of rapid and cost-effective processing of large sample volumes. Key models include Nextractor® NX-48S (48 samples in 10-25 minutes, 7-inch LCD touch screen, UV sterilization, 25kg), Nextractor® NX-Duo (24 or 96 samples in 15-30 minutes, capable of cfDNA extraction from 24 samples for liquid biopsy in 30-40 minutes, 6-inch touch screen, UV sterilization, 60kg), Nextractor® NX-Jr (1-8 samples in 15 minutes, compact design, UV sterilization, 12kg), and Nextractor® NX-48N (48 samples in 25 minutes).
- Nextractor® Nucleic Acid Extraction Kits: Reagent kits for extracting DNA/RNA from various sample types (sputum, cells, FFPE tissue, blood, saliva, stool, plant tissue, etc.). Designed for user convenience with pre-filled cartridges or well plates.Nextractor® Nucleic Acid Extraction Kits: Reagent kits for extracting DNA/RNA from various sample types (sputum, cells, FFPE tissue, blood, saliva, stool, plant tissue, etc.). Designed for user convenience with pre-filled cartridges or well plates.
- Double-stranded RNA (dsRNA) Synthesis Technology (AgroRNA): Provides large-scale dsRNA synthesis services for gene expression research and the development of eco-friendly pest control products.Double-stranded RNA (dsRNA) Synthesis Technology (AgroRNA): Provides large-scale dsRNA synthesis services for gene expression research and the development of eco-friendly pest control products.
- RNAi-based Therapeutics and Crop Protection Agent Development: Development and approval of 'Honeyguard-R solution' for the treatment of sacbrood disease in honeybees. Patent application for an RNA interference (RNAi)-based crop protection composition precisely targeting Tomato Spotted Wilt Virus (TSWV), which damages major crops like chili peppers and paprika.RNAi-based Therapeutics and Crop Protection Agent Development: Development and approval of 'Honeyguard-R solution' for the treatment of sacbrood disease in honeybees. Patent application for an RNA interference (RNAi)-based crop protection composition precisely targeting Tomato Spotted Wilt Virus (TSWV), which damages major crops like chili peppers and paprika.
- DNA Methylation Biomarker Technology: Domestic patent application for a novel DNA methylation biomarker capable of predicting malignant progression of precancerous cervical lesions. A precision medicine solution predicting high-grade lesions in hrHPV-infected women with over 94% accuracy.DNA Methylation Biomarker Technology: Domestic patent application for a novel DNA methylation biomarker capable of predicting malignant progression of precancerous cervical lesions. A precision medicine solution predicting high-grade lesions in hrHPV-infected women with over 94% accuracy.
- Core Advantages
- Unique Nucleic Acid Extraction Platform Technology: Capability to develop nucleic acid extraction platforms that process large volumes of samples quickly and cost-effectively. Specifically, Nextractor® NX-48 processes 48 samples in 15 minutes, offering superior efficiency compared to global competitors.Unique Nucleic Acid Extraction Platform Technology: Capability to develop nucleic acid extraction platforms that process large volumes of samples quickly and cost-effectively. Specifically, Nextractor® NX-48 processes 48 samples in 15 minutes, offering superior efficiency compared to global competitors.
- Comprehensive Product Lineup and Automation System: A diverse range of nucleic acid extraction instruments (NX-Jr, NX-48S, NX-Duo, NX-48N) with varying throughputs and applications, along with customized extraction kits, meeting diverse customer needs. Walk-away systems ensure user convenience and safety.Comprehensive Product Lineup and Automation System: A diverse range of nucleic acid extraction instruments (NX-Jr, NX-48S, NX-Duo, NX-48N) with varying throughputs and applications, along with customized extraction kits, meeting diverse customer needs. Walk-away systems ensure user convenience and safety.
- Leadership in RNAi-based Green Bio Sector: The only company in Korea to secure large-scale dsRNA production platforms, regulatory approval experience, and technical know-how. This capability positions the company to lead the next-generation green bio solution market, including honeybee disease treatments and eco-friendly crop protection agents.Leadership in RNAi-based Green Bio Sector: The only company in Korea to secure large-scale dsRNA production platforms, regulatory approval experience, and technical know-how. This capability positions the company to lead the next-generation green bio solution market, including honeybee disease treatments and eco-friendly crop protection agents.
- Strong Global Market Presence: Active international export through a network of over 70 distributors in more than 50 countries. Over 90% of total sales originate from overseas, with continuous orders for nucleic acid extraction instruments and reagents from markets in Europe and Asia.Strong Global Market Presence: Active international export through a network of over 70 distributors in more than 50 countries. Over 90% of total sales originate from overseas, with continuous orders for nucleic acid extraction instruments and reagents from markets in Europe and Asia.
- Continuous R&D and New Business Expansion: An R&D-focused company with over 30% of its workforce dedicated to research and development. Diversification of its pipeline into RNA-based AgBio platforms and precision oncology beyond molecular diagnostics, securing future growth engines.Continuous R&D and New Business Expansion: An R&D-focused company with over 30% of its workforce dedicated to research and development. Diversification of its pipeline into RNA-based AgBio platforms and precision oncology beyond molecular diagnostics, securing future growth engines.
- Successful Localization of Technology and Market Contribution: Successfully localized high-cost foreign nucleic acid extraction equipment and reagents, contributing to the development of the domestic bio-industry. Played a crucial role in K-quarantine efforts during the COVID-19 pandemic.Successful Localization of Technology and Market Contribution: Successfully localized high-cost foreign nucleic acid extraction equipment and reagents, contributing to the development of the domestic bio-industry. Played a crucial role in K-quarantine efforts during the COVID-19 pandemic.
- Target Industrie
- Molecular Diagnostics: Diagnosis of infectious diseases (COVID-19, influenza, STDs, etc.), cancer diagnosis, prenatal screening, etc..Molecular Diagnostics: Diagnosis of infectious diseases (COVID-19, influenza, STDs, etc.), cancer diagnosis, prenatal screening, etc..
- Genetic Testing: Analysis of genetic mutations, diagnosis of genetic diseases, gene expression studies, etc..Genetic Testing: Analysis of genetic mutations, diagnosis of genetic diseases, gene expression studies, etc..
- Life Science Research: Nucleic acid extraction and analysis from various biological samples (cells, tissues, blood, etc.).Life Science Research: Nucleic acid extraction and analysis from various biological samples (cells, tissues, blood, etc.).
- Agrochemical Industry: Development of RNAi-based pest control products, research and commercialization of eco-friendly crop protection agents.Agrochemical Industry: Development of RNAi-based pest control products, research and commercialization of eco-friendly crop protection agents.
- Veterinary Medicine: Development of animal pharmaceuticals such as treatments for honeybee sacbrood disease.Veterinary Medicine: Development of animal pharmaceuticals such as treatments for honeybee sacbrood disease.
- Precision Medicine: Real-time tracking of diseases like cancer through liquid biopsy, prediction of malignant progression of precancerous cervical lesions.Precision Medicine: Real-time tracking of diseases like cancer through liquid biopsy, prediction of malignant progression of precancerous cervical lesions.
- Major Markets
- South Korea, Japan, Malaysia, Hong Kong, UAESouth Korea, Japan, Malaysia, Hong Kong, UAE
- Germany (participated in MEDICA exhibition), Over 40 CB member countriesGermany (participated in MEDICA exhibition), Over 40 CB member countries
- United States (participated in AACC exhibition)United States (participated in AACC exhibition)
- Certifications/Patents
- Domestic patent acquisition for Nextractor® NX-Duo nucleic acid extraction device (September 13, 2022).Domestic patent acquisition for Nextractor® NX-Duo nucleic acid extraction device (September 13, 2022).
- Patent acquisition for nucleic acid extraction device and its driving control method (May 28, 2021).Patent acquisition for nucleic acid extraction device and its driving control method (May 28, 2021).
- Patent application for nucleic acid extraction single cartridge and nucleic acid extraction device (September 18, 2020).Patent application for nucleic acid extraction single cartridge and nucleic acid extraction device (September 18, 2020).
- Domestic patent application for RNAi-based crop protection composition (July 1, 2025).Domestic patent application for RNAi-based crop protection composition (July 1, 2025).
- Domestic patent application for DNA methylation biomarker (August 19, 2025).Domestic patent application for DNA methylation biomarker (August 19, 2025).
- CE and ISO 13485 certifications obtained (2013).CE and ISO 13485 certifications obtained (2013).
- GMP certification obtained (2017).GMP certification obtained (2017).
- Registration of automated nucleic acid extraction instrument with the Ministry of Health and Welfare in Malaysia (2019).Registration of automated nucleic acid extraction instrument with the Ministry of Health and Welfare in Malaysia (2019).
- CB certification for Nextractor® NX-DUO from KTC (July 7, 2022).CB certification for Nextractor® NX-DUO from KTC (July 7, 2022).
- Genetic testing institution certification obtained (December 19, 2024).Genetic testing institution certification obtained (December 19, 2024).
- CEO Kim Ki-ok simultaneously awarded the Gold Tower Industrial Medal and the 70 Million Dollar Export Tower on Trade Day (December 16, 2025).CEO Kim Ki-ok simultaneously awarded the Gold Tower Industrial Medal and the 70 Million Dollar Export Tower on Trade Day (December 16, 2025).
Introduction
Location
63 Magokjungang 8-ro 3-gil, Gangseo-gu, Seoul, South Korea
클릭하여 위치 살펴보기
